Wave Life Sciences Ltd.
Pitch Summary: Wave Life Sciences has shown promise with its RNA-based therapies, particularly with WVE-007 for obesity, which initially drove the stock price from $7.50 to $21. However, the stock has since normalized to $12 as investors reassess the clinical and regulatory risks inherent in early-stage biotech. The company’s diverse pipeline, including WVE-006 for alpha-1 […]
